PBLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Parabilis Medicines, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$25.35+2.60 (+11.43%)
Close on Oct 19, 2026
- Market cap
- $732.82M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | Before market open | $148.00K | $-2.32 | – |
Press releases
Announcements Parabilis Medicines filed with the SEC
Parabilis Medicines Appoints Accomplished Drug Development Leader Craig L. Tendler, M.D., to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Parabilis Medicines Reports Second Quarter 2026 Financial Results and Provides Business Updates
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Creating Extraordinary Medicines Drugging Previously Undruggable Intracellular Drivers of Serious Diseases August 2026
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K